6855 — Ascentage Pharma International Share News
0.000.00%
Last trade - 00:00- HK$11.38bn
- HK$11.63bn
- CNY574.12m
Brief: Ascentage Pharma Group International Repurchased Aggregate Of 178,400 Shares Of Co
Brief: Ascentage Pharma Group International Announces A Clinical Trial Collaboration And Supply Agreement With Pfizer
Brief: Ascentage Pharma Group International Repurchased Aggregate Of 180,000 Shares Of Co
Brief: Ascentage Pharma Group International Repurchased An Aggregate Of 178,000 Shares Of Co
Brief: Ascentage Pharma Says Repurchased 380,000 Shares For Hk$10.5 Million
Brief: Ascentage Pharma Group International Says Su Zhang Resigned As Chief Financial Officer
Brief: Ascentage Pharma Says Mdm2-P53 Inhibitor APG-115 Granted Fast Track Designation By U.S FDA
Brief: Ascentage Pharma Group International Posts HY Revenue RMB13.0 Million
Brief: Ascentage Pharma Group International Says MDM2-P53 Inhibitor, APG-115 Got An Orphan Drug Designation By U.S. FDA
Brief: Ascentage Pharma's Mdm2-P53 Inhibitor APG-115 (Alrizomadlin) Granted An Orphan Drug Designation By The FDA For The Treatment Of Stage Iib-Iv Melanoma, Marking The Twelfth Obtained By The Company
Brief: Ascentage Pharma Group International Establishes Cooperation With US National Cancer- Institute
Brief: Ascentage Pharma Group International Says To Grant To Innovent Suzhou Right To Develop Hqp1351
Brief: Innovent Biologics Inc Announces Strategic Collaboration With Ascentage Pharma Group International
Brief: Ascentage Pharma Group International Announces IND Clearance By US FDA
Brief: Ascentage Pharma Says Olverembatinib (HQP1351) Recommended For Breakthrough Therapy Designation
Brief: Ascentage Pharma Says BCR-ABL Inhibitor In China Recommended For Breakthrough Therapy Designation
HK-listed Ascentage Pharma falls on $144.5 mln share sale
Brief: Ascentage Pharma Group International Says To Place 26.5 Million Shares
Brief: Ascentage Pharma Group International Says U.S. FDA Granted APG-2575 Orphan Drug Designation